Kymera Therapeutics Inc. (KYMR)
NASDAQ (NMS) NASDAQ (NMS) Primary 
XKLS 
Gilead partners with Kymera to develop novel cancer therapy
Gilead Sciences Inc (NASDAQ:GILD, ETR:GIS) and Kymera Therapeutics (NASDAQ:KYMR) have entered into an exclusive option and license agreement focused on developing a novel cancer treatment targeting cyclin-dependent kinase 2 (CDK2), a protein that plays a key role in tumor growth. This collaboration aims to accelerate the development and commercialization of a new class of drugs called molecular glue degraders (MDGs), which work by selectively removing the CDK2 protein from cancer cells rather than merely inhibiting its function.
Analysts Can't Get Enough of These Little-Known Biopharma Stocks
The biopharmaceuticals industry is both exciting and risky for investors. Many leading growth stocks in the U.S. market are found in this sector, due to the significant rallies that biopharmaceutical companies experience when a key positive trial result is announced or an important drug receives government approval.
Kymera Stock Gains on Positive Data on Investigational Dermatitis Drug
KYMR jumps after KT-621 phase I data beats expectations, matching or topping Dupixent on key biomarkers in Th2 diseases.
Kymera: Positive Phase 1 KT-621 Study Leads To Q4 2025 AD Treatment Data
Kymera Therapeutics' KT-621 demonstrated strong proof-of-concept as an oral STAT6 degrader, showing biologic-like efficacy in phase 1 healthy volunteer data. Results from phase 1b BroADen study, using KT-621 to target patients with moderate-to-severe atopic dermatitis, expected Q4 of 2025. Robust pipeline in place, including a Sanofi partnership on KT-474 and a new IRF5 degrader, diversifies its immunology targeting market opportunity.
Kymera Therapeutics: Intriguing Degradation Thesis, But A Bit Powder Puff
I'm downgrading Kymera to 'Hold' due to slow clinical progress, pipeline uncertainty, and lack of near-term catalysts despite strong cash position. Kymera's unique focus on immunology with oral protein degraders offers potential, but faces entrenched competitors and unproven clinical efficacy. Sanofi's advancement of KT-474 is positive, but may be more about testing protein degradation's threat to Dupixent than a strong endorsement.
Kymera Therapeutics, Inc. (KYMR) Q1 2025 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q1 2025 Earnings Conference Call May 9, 2025 10:00 AM ET Company Participants Justine Koenigsberg - Vice President of Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Veronica Campbell - Senior Director of Immunology Conference Call Participants Jeet Mukherjee - BTIG Marc Frahm - TD Cowen Eliana Merle - UBS Securities Sudan Loganathan - Stephens Vikram Purohit - Morgan Stanley Eric Joseph - JPMorgan Faisal Khurshid - Leerink Partners Michael Schmidt - Guggenheim Andy Chen - Wolfe Research Kalpit Patel - B. Riley Justine Koenigsberg Good morning and welcome to Kymera's Immunology Innovation Day, our virtual event to introduce our next immunology program, IRF5.
Kymera' s Q1 Loss Narrower Than Expected, Pipeline Progress Encouraging
Kymera reports a narrower-than-expected loss for the first quarter of 2025. The company expects the current cash balance to provide a runway into the first half of 2028.
Kymera Therapeutics, Inc. (KYMR) Reports Q1 Loss, Tops Revenue Estimates
Kymera Therapeutics, Inc. (KYMR) came out with a quarterly loss of $0.82 per share versus the Zacks Consensus Estimate of a loss of $0.92. This compares to loss of $0.69 per share a year ago.
Why Kymera Therapeutics Stock Crushed it This Week
According to data compiled by S&P Global Market Intelligence, Kymera Therapeutics (KYMR -0.86%) notched an almost 23% share price gain across this week. That made it a standout in the ever-volatile biotech sector.
Kymera Therapeutics (KYMR) Moves 13.8% Higher: Will This Strength Last?
Kymera Therapeutics (KYMR) witnessed a jump in share price last session on above-average trading volume. The latest trend in earnings estimate revisions for the stock doesn't suggest further strength down the road.
Kymera's Q4 Loss Wider Than Expected, Pipeline in Focus
KYMR reports a wider-than-expected loss for the fourth quarter of 2024. The company expects the current cash balance to provide a runway into mid-2027.
Kymera Therapeutics, Inc. (KYMR) Q4 2024 Earnings Call Transcript
Kymera Therapeutics, Inc. (NASDAQ:KYMR ) Q4 2024 Earnings Conference Call February 27, 2025 8:30 AM ET Company Participants Justine Koenigsberg - Vice President-Investor Relations Nello Mainolfi - Founder, President & Chief Executive Officer Jared Gollob - Chief Medical Officer Bruce Jacobs - Chief Financial Officer Conference Call Participants Faisal Khurshid - Leerink Partners Andy Chen - Wolfe Research Paul Jeng - Guggenheim Ron Feiner - JPMorgan Jeff Jones - Oppenheimer Brad Canino - Stifel Marc Frahm - TD Cowen Ellie Merle - UBS Securities Parth Patel - Morgan Stanley Kripa Devarakonda - Truist Securities Eva Fortea-Verdejo - Wells Fargo Eric Wong - Goldman Sachs Jeet Mukherjee - BTIG Sudan Loganathan - Stephens Operator Good day everyone. My name is Megan and I will be your conference operator today.
